Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bjs.1800590206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent Hypophosphatemia Following a Single Dose of Parenteral Iron Administration.
Cureus
November 2024
Acute Medicine, Royal Stoke University Hospital, Stoke-on-Trent, GBR.
Although parenteral iron is widely used to treat iron deficiency anemia (IDA), some side effects have been inadequately explored. Hypophosphatemia is becoming a well-documented, yet poorly understood, side effect of parenteral iron infusion, oftentimes causing serious and/or prolonged complications. In this article, we discuss the case of a 33-year-old female with IDA who suffered debilitating physical and mental symptoms of significant recurrent hypophosphatemia following a single standard dose of parenteral iron administration.
View Article and Find Full Text PDFSafety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers.
Malar J
October 2024
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand.
Background: Parenteral artesunate is the first-line therapy for severe malaria. Artesunate, in its current formulation, must be prepared immediately before administration by first dissolving in sodium bicarbonate solution and then diluting in saline. A novel solvent for rapid and stable single step reconstitution of artesunate was recently developed showing improved solubility and stability.
View Article and Find Full Text PDFPharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects.
Int J Antimicrob Agents
November 2024
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Antibiotic Clinical Pharmacology of the National Health Commission, Shanghai, China; National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China; Research Ward of Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
Objective: Increasing antimicrobial resistance has led to the revival of the polymyxins as a last-resort therapeutic option for multidrug-resistant Gram-negative bacterial infections. A parenteral formulation of colistin sulfate is available solely in China. While the onset of action of IV colistin may occur faster than with its prodrug CMS, its pharmacokinetic (PK) profile remains unclear.
View Article and Find Full Text PDFComparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial.
Eur J Pharm Sci
December 2024
Medical Department, FAES FARMA S. A., Leioa (Vizcaya), Spain. Electronic address:
Article Synopsis
- Bilastine is a non-sedating antihistamine effective for treating allergies, and this study aimed to compare its different formulations (i.v., i.m., and oral) against dexchlorpheniramine and placebo for their antihistamine activity and onset time.
- Conducted on 25 healthy adults, the study demonstrated that all bilastine formulations provided quick relief (15 min for i.v. and i.m., 30 min for oral) and significantly reduced allergic reactions compared to dexchlorpheniramine and placebo.
- The results showed that bilastine formulations were not only more effective but also safe, with no serious adverse events reported, while dexchlorpheniramine was
Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network.
Glob Reg Health Technol Assess
July 2024
Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara - Italy.
Article Synopsis
- The study investigates the effectiveness and economic benefits of using dalbavancin for treating acute bacterial skin infections compared to standard treatments, highlighting the potential for early patient discharge.
- It analyzed data from patients treated with dalbavancin at a hospital in Italy over six years, demonstrating its role in reducing hospital stays and improving antibiotic adherence.
- Findings suggest that dalbavancin can save over €3,200 per patient by facilitating quicker discharges while managing complex infections effectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!